Add To Watchlist
Share URL
About The Company
Description
Implanet S.A.
Read More
Overview
Value
1
Growth
30
Health
27
Management
50
Analyst Opinion
71
Total
36
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders
- Has a high level of debt 0
- Poor overall financial health
- No margin of safety at their current market price
- Poor earnings and cashflow growth
- Accounting anomalies: Growing revenues without a corresponding growth in cash flows. 0
Market Peers
ALIMP.PA
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-2013076368910595.75%
Revenue Growth (5 Year Average)
2.13%
Ratings Consensus
Buy
Share Buybacks
-2451.31%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 0.2 EUR
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-71.09%
PE/Earnings Growth
N/A
Price/Book
2.11x
Growth
Growth Score
30
- ✔ 5 Year Average Earnings growth of 24.62% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of 2.13% is lower than the market average (10.97%)
- ✘ Revenue growth has slowed this year
- ✘ 5 Year Average Free Cashflow growth of -15.62% is lower than the market average (12.35%)
Revenue Growth
2.13%
Earnings Growth
24.62%
Cashflow Growth
-15.62%
Health
Health Score
27
Altman Z Score
N/A
Piostroski Score
3.00
Debt/Equity
3.43x
Current Assets/Liabilities
1.09x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
1.11x
Management
Management Score
50
Average Buybacks/Dilution
-2451.31%
Recent Buybacks/Dilution
-60.98%
5 Year Price Volitility
51.56%
Return On Assets
-10.74%
Return On Capital Employed
-25.09%
Return On Equity
-63.97%
Return On Free Cashflow
55.16%
Return On Investments
N/A
Analysts
Analyst Opinion
71
- ✔ Ratings consensus is Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Currency
EUR
Beta
Vol Avg
Ceo
Mr. Ludovic Lastennet
Cik
Cusip
F5R535140
Exchange
Paris
Full Time Employees
Industry
Medical Devices
Sector
Healthcare
Ipo Date
Address
Technopole Bordeaux Montesquieu, Allee Francois Magendie
City
Martillac
State
NOUVELLE-AQUITAINE
Country
Zip
33650
Phone
33557995555
All financial data provided by FMP